FundedIQ
Biotechnology

Bambusa Therapeutics: Funding, Investors & Team (Sep 2026)

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.

www.bambusatx.com Boston, United States
Biotechnology Health Care Life Science Medical
Total raised
$90.0M
Rounds
2
Latest
Series A
Nov 2025

Bambusa Therapeutics has raised $90.0M across 2 funding rounds on record, the most recent a Series A announced in Nov 2025.

Bambusa Therapeutics Company Profile and Key Stats

Total funding raised
$90.0M
across 2 rounds on record
Funding rounds on record
2
1 with no disclosed amount
Latest funding round
Series A
Nov 2025
Headquarters
Boston, United States

Latest funding round on record: Nov 2025.

Bambusa Therapeutics Funding Rounds

Date
Round
Amount
Series A
Undisclosed
Series A
$90.0M

1 of 2 rounds was announced without a disclosed amount and is excluded from the total.

Bambusa Therapeutics raised $90.0M in a Series A announced in Feb 2025.

9 months later, a Series A was announced in Nov 2025 with no disclosed amount.

Bambusa Therapeutics Founders and Leadership Team

Name
Role
Contact
Helmut Jeggle
Founder
Shanshan Xu, MD, PhD
Locked

Contact details for the Bambusa Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.

Start 14-day free trial →

Bambusa Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
8,378
$15M

Funded Startups Like Bambusa Therapeutics in Biotechnology and Boston

Companies Similar to Bambusa Therapeutics

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Bambusa Therapeutics Funding FAQs

What does Bambusa Therapeutics do?

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.

How much funding has Bambusa Therapeutics raised?

Bambusa Therapeutics has raised $90.0M across 2 rounds on record.

When did Bambusa Therapeutics last raise funding?

Bambusa Therapeutics' most recent funding round on record was announced in Nov 2025. The amount was not disclosed.

Who founded Bambusa Therapeutics?

FundedIQ lists Helmut Jeggle (Founder) at Bambusa Therapeutics.

Where is Bambusa Therapeutics headquartered?

Bambusa Therapeutics is based in Boston, Massachusetts, United States.

About FundedIQ's Bambusa Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bambusa Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.